2026/0221-Invitation to submit proposals under framework agreement(s) 2023/494 - Medicines for chronic Hepatitis C and 2025/1303 - Various medicines for the procurement of medicines for chronic Hepatitis C

This tender, reference 2026/0221, is an invitation for proposals related to the procurement of medicines for chronic Hepatitis C. It specifies that the procurement will be conducted under two existing framework agreements: 2023/494 (Medicines for chronic Hepatitis C) and 2025/1303 (Various medicines). This indicates that the procuring entity is leveraging established agreements to acquire these critical pharmaceuticals. The primary focus is on obtaining medications to treat chronic Hepatitis C, a serious liver infection. The inclusion of the second framework agreement suggests that a broader range of "various medicines" might also be procured if needed, or that it complements the specific Hepatitis C agreement. The tender aims to secure a supply of effective treatments for patients suffering from this condition. Bidders are likely pharmaceutical companies or distributors who are parties to or eligible to bid under these framework agreements. The proposals will be evaluated based on factors such as price, availability, delivery timelines, and compliance with pharmaceutical quality standards.

This is a supplies contract in the health and medical services, information and communication technology and general supplies sectors. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 187,000.

Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.